SCHEMBL6432007

SCHEMBL6432007

COc1ccc(O)c(C(=NN)c2nc3nonc3nc2Nc2ccc(F)cc2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.41
TP53 P04637 2/20 0.41
MAPT P10636 2/20 0.41
TLR4 O00206 2/20 0.41
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
RAB9A P51151 2/20 0.39
ALOX15 P16050 2/20 0.39
HSD17B10 Q99714 2/20 0.39
KDM4E B2RXH2 1/20 0.39
NPC1 O15118 1/20 0.39
USP2 O75604 1/20 0.39
ALOX12 P18054 1/20 0.39
HTT P42858 1/20 0.39
AURKA O14965 2/20 0.37
ABCG2 Q9UNQ0 2/20 0.36
PLAU P00749 2/20 0.35
RXFP1 Q9HBX9 1/20 0.35
ATM Q13315 1/20 0.34
HTR2C P28335 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6438171 0.93 TLR4 (0.41) SMN1; SMN2TP53MAPTTLR4MEN1
SCHEMBL6439214 0.90 MEN1 (0.38) SMN1; SMN2TP53MAPTMEN1KMT2A
SCHEMBL6439207 0.90 MEN1 (0.38) SMN1; SMN2TP53MAPTMEN1KMT2A
SCHEMBL6417864 0.89 APP (0.42) SMN1; SMN2TP53MAPTMEN1KMT2A
SCHEMBL6417043 0.88 SMN1; SMN2 (0.38) SMN1; SMN2TP53MAPTMEN1KMT2A
SCHEMBL6418390 0.85 MAPT (0.41) SMN1; SMN2TP53MAPTMEN1KMT2A
SCHEMBL6418411 0.85 P2RX1 (0.41) SMN1; SMN2TP53MAPTTLR4MEN1
SCHEMBL6418380 0.85 MAPT (0.41) SMN1; SMN2TP53MAPTMEN1KMT2A
SCHEMBL6418425 0.85 P2RX1 (0.41) SMN1; SMN2TP53MAPTTLR4MEN1
SCHEMBL6435499 0.85 FADS1 (0.48) SMN1; SMN2TP53MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 SMN1; SMN2 4369/4885TP53 4485/4885MAPT 4420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.